Plasma Protein Therapeutics Market Size, Share, Growth, Trends, Consumption, Production, Revenue and Forecast 2022 - 2030

The Plasma Protein Therapeutics Market size was valued at US$ 24.38 billion in 2021 and is expected to reach US$ 52.15 billion by 2030 with a CAGR of 7.6% from 2022 to 2030.

Growing Investment in Innovation, Rising Demand for Immunoglobulin (IG), Rising Indications and Therapeutic use of Plasma Derived Protein Therapeutics are projected to drive the plasma protein therapeutics market.

Overview

• Plasma-derived therapies and their recombinant analogs, collectively referred to as plasma protein therapies, are unique, biologic medicines, versus synthetic or chemical medicines, because production begins with plasma, a biologic starting material.
• Stringent Regulations and Reimbursement Issues, diagnosis rate, public awareness and high price of the biological are the major market barrier. High demand in plasma protein therapeutic proteins and medicinal use in new indications, penetration of existing indications, better access to medicines in emerging markets, aging population, and new plasma-derived therapies are likely to drive the market.
• North America is poised to cover a high share in 2018, while Asia Pacific is poised to grow at a highest CAGR in the forecast. The growth of plasma derived market in North America is mainly due to increasing IVIG sales during the forecast period. There is a growing demand of Albumin in Asia Pacific market, followed by Latin America.

Growing Investment in Innovation, Rising Demand for Immunoglobulin (IG) and Rising Indications and Therapeutic use of Plasma Derived Protein Therapeutics to Drive Market

• The plasma protein industry has been investing in research and development of new plasma proteins therapies (e.g.: Ceruloplasmin, IgA, Plasmin) leading to innovative treatments for the benefits of patients. In March 2016, Grifols announced that it will invest US$ 360 Mn to expand its production capabilities for plasma-derived therapies. The investment will increase the plasma fractionation capacity and purification of several proteins. Thus this factors drive the growing investment in innovation.
• Plasma-derived IG is used for a wide range of autoimmune and inflammatory diseases. Increased recognition and treatment of immune deficiencies in developing world have added to the global demand for IG. However, increased use of high dose therapy, particularly in autoimmune neurologic diseases is the major reason for the continued strong growth in demand for IG products. Thus this factors drive the demand for immunoglobulin.
• Plasma protein therapies are used in the treatment of rare diseases. The therapies include: Immunoglobulin's used to treat a number of diseases in individuals with immune deficiencies and autoimmune diseases, Clotting-factor therapies used for individuals with hemophilia A and B and other bleeding disorders, Albumin, which is used in acute settings to treat individuals with shock, trauma, burns and other conditions. Thus this factors drive the plasma protein therapeutics and their uses.

Immunoglobulin Segment to Dominate Market

• Based on product type, the Plasma Protein Therapeutics Market has been divided into Immunoglobulin, Albumin, Coagulation Factor, C1-esterase inhibitors and others. The Immunoglobulins are plasma derived molecules, which account for a major share of the plasma derived protein products market. Intravenous immunoglobulin (IVIG) is a major product derived from large pools of human plasma containing antibodies against a broad spectrum of bacterial and viral agents. High global demand for IVIG is due to increased usage in primary immunodeficiency and neurological applications. The Immunoglobulins segment dominated the Plasma Protein Therapeutics Market in 2018 and the trend is projected to continue during the forecast period.

Hereditary Angioedema to be Highly Lucrative Segment

• In terms of applications, the Plasma Protein Therapeutics Market has been classified into Hemophilia, "Primary Immunodeficiency Disorder (PID)", "Idiopathic Thrombocytopenic, Purpura", Secondary Immunodeficiency, Hereditary Angioedema, Other applications.
• Hereditary angioedema (HAE) is a rare disorder caused by C1 esterase inhibitor deficiency. It accounts for only 2% of clinical angioedema cases. In type 1 and type 2 cases of hereditary angioedema, the former is the 85% of the cases. The worldwide incidence of HAE is approximately 1 in 30,000 to 50,000 persons. Growing awareness and treatment rate is expected to drive the segment.

North America to Dominate Global Market

• In terms of region, the Plasma Protein Therapeutics Market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the Plasma Protein Therapeutics Market in 2018, followed by Europe.
• The immunoglobulin segment accounted for the largest share of the market in North America in 2015. The C1 esterase inhibitors segment is poised to expand at a high CAGR, followed by the albumin segment during the forecast period. The coagulation factor (VIII and IX) segment would decline at a CAGR of 7.8% due to increasing trend in usage of recombinant proteins and rising FDA approvals.
• Albumex and Buminate are the key brands in North America. Increasing therapeutic usage in new indications such as cirrhosis, acute liver failure, and amyotrophic lateral sclerosis is likely to drive the market. Moreover, the FDA approval for capacity expansion is expected to propel the market. For instance, CSL Ltd. received FDA approval for Albumin capacity expansion in Kankakee, U.S. that would automatically increase production, thus boosting market growth in the U.S.

 Competitive Landscape

• The Plasma Protein Therapeutics Market is fragmented in terms of number of players. Key players in the global market include Baxter International, Biotest, CSL Behring, GRIFOLS, S.A., Kedrion, Octapharma USA, Inc., Shire Plc., China Biologics and  among others

Market Segmentation:

By Product Type

• • Immunoglobulin
  • Albumin
  • Coagulation Factor
  • C1-esterase inhibitors
  • Others

By Application

• • Hemophilia
  • "Primary Immunodeficiency
  • Disorder (PID)"
  • "Idiopathic Thrombocytopenic
  • Purpura"
  • Secondary Immunodeficiency
  • Hereditary Angioedema
  • Other applications

By Region

• • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific          
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

A new study on the global plasma protein therapeutics market has been published by Vision Research Reports. It presents a wealth of information on key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the global plasma protein therapeutics market. The study offers valuable information about the global plasma protein therapeutics market to illustrate how the market would grow during the forecast period 2020-2027. The report provides the value and volume of the global plasma protein therapeutics market for the period 2020–2027, considering 2020 as the base year and 2027 as the forecast year. The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study.

Key indicators of market growth, which include value chain as well as supply chain analyses, and Compound Annual Growth Rate (CAGR), are elucidated in the study in a comprehensive manner. This data can help readers interpret quantitative growth aspects of the global plasma protein therapeutics market during the forecast period.

An extensive analysis on business strategies of leading market players is also featured in study on the global plasma protein therapeutics market. This can help readers understand principal factors to foresee growth in the global plasma protein therapeutics market. In this study, readers can also find specific data on the qualitative and quantitative growth avenues for the global market, which is expected to guide market players in making apt decisions in the future.

The report also delves into the competition landscape of the global plasma protein therapeutics market. Key players operating in the global market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global market report.

Key Questions Answered in Plasma protein therapeutics Market Study

- What are the key factors influencing the plasma protein therapeutics market in each region?

- What will be the CAGR of the global plasma protein therapeutics market between 2016 and 2027?

- What is the future scope and changing trends in technologies in the global plasma protein therapeutics market?

- Which factors will impede the growth of the global plasma protein therapeutics market during the forecast period?

- Which are the leading companies in the global plasma protein therapeutics market?

- Which region is set to expand at the fastest CAGR during the forecast period?

- What is the volume (Units) of different plasma protein therapeutics across all regions during the forecast period?

- Which segment will have the highest revenue globally in 2027 and which segment will expand at the fastest CAGR during the forecast period?

Research Methodology

A unique research methodology has been utilized by Vision Research Reports to conduct a comprehensive research on the growth of the global plasma protein therapeutics market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary sources referred to by analysts during the production of the global plasma protein therapeutics market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.

These primary and secondary sources provided exclusive information during interviews, which serves as a validation from plasma protein therapeutics industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped in making Vision Research Reports estimates on the future prospects of the global market more reliable and accurate.